Cargando…
Exploring the Surface of the Ectodomain of the PD-L1 Immune Checkpoint with Small-Molecule Fragments
[Image: see text] Development of small molecules targeting the PD-L1/PD-1 interface is advancing both in industry and academia, but only a few have reached early-stage clinical trials. Here, we take a closer look at the general druggability of PD-L1 using in silico hot spot mapping and nuclear magne...
Autores principales: | Kitel, Radoslaw, Rodríguez, Ismael, del Corte, Xabier, Atmaj, Jack, Żarnik, Magdalena, Surmiak, Ewa, Muszak, Damian, Magiera-Mularz, Katarzyna, Popowicz, Grzegorz M., Holak, Tad A., Musielak, Bogdan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2022
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486809/ https://www.ncbi.nlm.nih.gov/pubmed/36073782 http://dx.doi.org/10.1021/acschembio.2c00583 |
Ejemplares similares
-
PD-L1 Inhibitors: Different Classes, Activities, and Mechanisms of Action
por: Surmiak, Ewa, et al.
Publicado: (2021) -
Terphenyl-Based
Small-Molecule Inhibitors of Programmed
Cell Death-1/Programmed Death-Ligand 1 Protein–Protein Interaction
por: Muszak, Damian, et al.
Publicado: (2021) -
Computer- and NMR-Aided Design of Small-Molecule Inhibitors of the Hub1 Protein
por: Reyes Romero, Atilio, et al.
Publicado: (2022) -
Design, Synthesis, and Biological Evaluation of Imidazopyridines
as PD-1/PD-L1 Antagonists
por: Butera, Roberto, et al.
Publicado: (2021) -
Competition NMR for Detection of Hit/Lead Inhibitors of Protein–Protein Interactions
por: Musielak, Bogdan, et al.
Publicado: (2020)